読み込み中
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
通常取引
$1.21
−$0.02 · -1.63%
日中の時刻はETです。市場データは遅延する場合があります。
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
日中レンジ
現在 $1.21
52週レンジ
現在 $1.21
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
48
適正価値
センチメント
41
まちまち
リスク
69
高リスク
モメンタム
30
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
日中レンジ
現在 $1.21
52週レンジ
現在 $1.21
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 250.1万 USD | — | 250.1万 USD | — | — |
| 粗利益 | −250.1万 USD | — | −250.1万 USD | — | — |
| 研究開発 | 1021.1万 USD | 1696.2万 USD | 1682.7万 USD | 1406.2万 USD | 734.7万 USD |
| 販売・一般管理 | 965万 USD | 1263.7万 USD | 1351万 USD | 1445.9万 USD | 730.6万 USD |
| 営業費用 | 1736万 USD | 3043.7万 USD | 2783.6万 USD | 2852.1万 USD | 1465.3万 USD |
| 受取利息 | 42.1万 USD | 23万 USD | — | — | — |
| 減価償却費と償却費 | 250.1万 USD | 265.5万 USD | 250.1万 USD | 110.3万 USD | 78.8万 USD |
| 営業利益 | −1986.1万 USD | −3043.7万 USD | −3033.7万 USD | −2852.1万 USD | −1465.3万 USD |
| 純利益 | −1944万 USD | −3043.7万 USD | −3000.7万 USD | −2852.1万 USD | −1465.3万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.00
上昇余地（230.58%）評価サンプルは4件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年6月6日 | 1:30 | — | — |
発効済み 2025年6月6日
1:30
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
